Kronos Bio 2024年第四季度GAAP每股收益$(0.43),未达预期$(0.38),销售额$227万,未达预期$242万

财报速递
19 Mar
Kronos Bio(NASDAQ:KRON)报告季度亏损$(0.43)每股,这比分析师的共识预估$(0.38)低了13.16%。这与去年同期持平。公司报告季度销售额为227万美元,比分析师的共识预期242万美元低6.20%。与去年同期的228.6万美元相比,这一下降了0.70%。

以上内容来自Benzinga Earnings专栏,原文如下:

Kronos Bio (NASDAQ:KRON) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.38) by 13.16 percent. This is unchanged from the same period last year. The company reported quarterly sales of $2.270 million which missed the analyst consensus estimate of $2.420 million by 6.20 percent. This is a 0.70 percent decrease over sales of $2.286 million the same period last year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10